Clinical trial
The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing…
NCT00002299 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00002299 |
|---|---|
| Title | The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS |
| Official title | Combination Therapy With 9-(1,3-Dihydroxy-2-Propoxymethyl) Guanine (DHPG) and Interferon Beta for the Prevention of Relapse of Cytomegalovirus Retinitis in Patients With the Acquired Immunodeficiency Syndrome |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Cytomegalovirus Retinitis, HIV Infections |
| Intervention type | Drug |
| Interventions | Interferon beta-1b, Ganciclovir |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: